Evercore ISI lowered the firm’s price target on Zimmer Biomet to $115 from $130 and keeps an In Line rating on the shares in an earnings preview for the MedTech, Life Science Tools and Diagnostics group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZBH:
- Zimmer Biomet Enhances Liquidity with New Credit Facilities
- Zimmer Biomet downgraded to Neutral from Overweight at Piper Sandler
- Zimmer Biomet Expands Board, Welcomes Devdatt Kurdikar
- Zimmer Biomet and RevelAi Health announce agreement
- Zimmer distribution agreement with THINK ‘makes sense,’ says Baird